GAMMA Investing’s SpringWorks Therapeutics SWTX Stock Holding History

GAMMA Investing’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-157	Closed	-$7.38K	–	3926
2025 Q2	$7.38K	Sell	157 -146	-48%	-$6.5K	﹤0.01%	2961
2025 Q1	$13.4K	Buy	303 +202	+200%	+$9.3K	﹤0.01%	2601
2024 Q4	$3.65K	Buy	101 +35	+53%	+$1.22K	﹤0.01%	3030
2024 Q3	$2.12K	Buy	66 +13	+25%	+$486	﹤0.01%	3052
2024 Q2	$2K	Sell	53 -21	-28%	-$884	﹤0.01%	2882
2024 Q1	$3.64K	Buy	74 +40	+118%	+$1.85K	﹤0.01%	2535
2023 Q4	$1.5K	Buy	+34	New	+$887	﹤0.01%	2672

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

GAMMA Investing's SWTX Position: Q3 2025 in Review

GAMMA Investing sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 157 shares — an estimated $7.38K sold.

GAMMA Investing first reported a position in SWTX in Q4 2023 and held it in 7 quarters. The position peaked at $13.4K in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

GAMMA Investing reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
GAMMA Investing sold 157 SpringWorks Therapeutics shares in Q3 2025, an estimated $7.38K.
GAMMA Investing first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 7 quarters.
GAMMA Investing's SpringWorks Therapeutics position peaked at $13.4K in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on GAMMA Investing's 13F filing for Q3 2025, filed 2 Oct 2025.